BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines non-GAAP Adjusted Operating Income (Loss) ($M) ($M)
Form 8-K EX-99.1 Non-GAAP Reconciliation Tables
Latest, Q2 2026
503
Period ended Jun 30, 2026
Change on a year earlier
+83.0%
275 in Q2 2025
History
15 quarters
Since Q4 2022
Sources
11
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP Adjusted Operating Income (Loss) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 503 | +83.0% | Form 8-K (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 414 | +197.4% | Form 8-K (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 344 | +338.2% | Form 8-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 341 | +419.9% | Form 8-K (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 275 | +467.3% | Form 8-K (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 139 | -194.6% | Form 8-K (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 78.6 | -129.4% | Form 8-K (filed 2025-02-27) ↗ |
| Q3 2024 | Sep 30, 2024 | 65.6 | -501.7% | Form 8-K (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 48.5 | -125.1% | Form 8-K (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | -147 | -46.6% | Form 8-K (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | -267 | -28.3% | Form 8-K (filed 2024-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | -16.3 | – | Form 8-K (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | -193 | – | Form 8-K (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | -276 | – | Form 8-K (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | -372 | – | Form 8-K (filed 2024-02-26) ↗ |
Breakdown
What makes up non-gaap adjusted operating income (loss) ($m)
Cite this data
StockData. (2026). BeOne Medicines Non-GAAP Adjusted Operating Income (Loss) ($M) ($M), quarterly Q4 2022–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/adj_op_inc
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.